Skip to main content
About Us
Overview
Leadership Team
Board of Directors
Clinical Advisory Board
Our Approach
PDE4 Prodrug
Publications
Pipeline
Overview
PALI-2108
Investors & News
Overview
Press Releases
Events & Presentations
Analyst Coverage
SEC Filings
Corporate Governance
IR Resources
Stock Information
FAQs
Email Alerts
Contact
The Microbiome-Activated Phosphodiesterase (PDE)-4 Inhibitor, PALI-2108 Leads to Rapid Clinical and Histologic Improvement in Moderate-to-Severe Ulcerative Colitis: A Phase1a/1b Study
brandedpixel
September 4th, 2026
No Comments
Comments are closed